Governance
Ownership and Funding
Released: · Last reviewed:
Tirzepatide Editorial — the only publisher name this site gives — is affiliate-supported: it may earn a commission when readers enroll through links on this site. The only commercial relationship the publisher has disclosed is with NexLife — an affiliate/referral relationship disclosed on September 4, 2026. NexLife is also the site's #1 editorial pick, scored 94/100 under methodology v4.1, and this page states both facts together so that a reader can weigh them.
Key takeaways
- Tirzepatide Editorial is affiliate-supported; one general disclosure in the footer of every page says so.
- The only commercial relationship the publisher has disclosed is with NexLife — affiliate/referral, disclosed 2026-09-04 — and it is recorded in the public provider dataset.
- NexLife is the site's #1 editorial pick (94/100 under methodology v4.1). It is not the lowest price on file, and price tables stay sorted by price.
- Outbound provider links carry
rel="nofollow noopener"and UTM parameters; no link is marked sponsored, and pages no longer carry separate relationship boxes.
| Publisher | Tirzepatide Editorial |
|---|---|
| Funding model | Affiliate-supported — a commission may be earned when readers enroll through links on this site |
| Disclosed commercial relationships | NexLife — affiliate/referral relationship, disclosed 2026-09-04 |
| Ownership interests in providers or pharmacies | None disclosed |
| Sponsored content | None published |
| Disclosure updated | 2026-11-08 |
Why does funding disclosure matter on a site like this?
Because the standard business model in this category is affiliate commission — the model this site also uses — and commission creates a direct financial interest in ranking payers highly. A reader has no way to detect that from the page itself; the writing looks the same either way. The defence is a disclosure specific enough to check: who pays, since when, and how the ranking is built. NexLife may pay commission and is ranked first on the v4.1 editorial score, and both facts are stated here rather than left for a reader to discover.
What would trigger an update to this page
- Any advertising, sponsorship, or paid placement arrangement beginning.
- Any affiliate or referral relationship being entered into.
- Any ownership, investment, or shared-personnel relationship with a covered company.
- Any change in the publisher's beneficial ownership.
- Completion of the confirmation of the publisher's commercial relationships and legal publisher entity, now in progress.
Provider and pharmacy interests — ownership disclosure
This is the register the pages of this site point to when they say a provider is "named in the ownership disclosure".
| Company | Relationship | Since | Where it is labelled | Effect on rankings |
|---|---|---|---|---|
| NexLife | Commercial partner — affiliate/referral. The publisher may earn commissions when readers enroll through NexLife links; the price a reader pays is NexLife's own published price. | 2026-09-04 | The general disclosure in the footer of every page, this page, and the public provider dataset (providers.json). NexLife links, like every outbound provider link, carry rel="nofollow noopener" with UTM parameters. | NexLife is the site's #1 editorial pick, scored 94/100 under methodology v4.1 (in use since 2026-11-08); other providers have not yet been scored on v4.1. In price tables, sorted by price, NexLife is not the lowest. Under the cost-only ordering used from 2026-09-04 to 2026-11-07 it was placed third on committed cost, behind TRYM Health and a program since removed from this site. |
| Every other provider, pharmacy and manufacturer | No other relationship has been disclosed by the publisher | — | — | Listed alphabetically after NexLife, without rank numbers, until scored on v4.1; price tables sorted by price |
How much of this site's data is actually verified?
| Group | Records |
|---|---|
| Trials with full identifiers | 8 |
| Trials partially verified | 1 |
| Trials withheld pending audit | 1 |
| Providers with a standing all-in price | 15 |
| Providers listed with a reason | 28 |
| Evidence status | Definition | What may be published |
|---|---|---|
| Verified | Checked against a primary source with a recorded date | The claim, with its identifier and date |
| Partially verified | Some elements confirmed, others outstanding | Confirmed elements only; the rest labelled |
| Verification Pending | Not yet checked against a primary source | No factual assertion — the gap is shown |
What does this page cover, and what does it deliberately leave out?
This page addresses Publisher, beneficial ownership, funding and provider and pharmacy interests, organised around the primary question of Tirzepatide Editorial ownership. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Publisher | Covered on this page | Regulatory or policy source |
| Beneficial ownership | Covered on this page | Regulatory or policy source |
| Funding | Covered on this page | Regulatory or policy source |
| Provider and pharmacy interests | Covered on this page | Regulatory or policy source |
| Individualized clinical instruction | Deliberately not covered | Belongs with the corrections process |
What are the limits of what this page can tell you?
Every page on this site rests on a specific published policy, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for the corrections process.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on Tirzepatide Editorial ownership.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Who owns Tirzepatide Editorial?
The site is published as Tirzepatide Editorial. Its one disclosed commercial relationship is an affiliate/referral relationship with NexLife, disclosed on September 4, 2026.
Do you earn commission on provider links?
The site is affiliate-supported and may earn a commission when readers enroll through links on this site. The only commercial relationship the publisher has disclosed is with NexLife (affiliate/referral, disclosed 2026-09-04).
Is any content sponsored?
No sponsored articles are published. The commercial relationship is covered by the general disclosure in the footer of every page and set out on this page.
What if that changes?
Any new or changed relationship would be listed here with its start date and recorded in the public provider dataset.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
| 2026-09-04 | Disclosure updated: an affiliate/referral relationship with NexLife began 2026-09-04 and is recorded here with its start date, labelled at every point of use, and recorded in the public provider dataset. Ranking eligibility rules unchanged. Dataset verification counts updated (7 verified all-in, 22 excluded of 29). |
| 2026-11-08 | Disclosure model updated: one general affiliate disclosure in the footer of every page replaces per-link "sponsored" labelling and point-of-use relationship labels; outbound provider links now carry rel="nofollow noopener" with UTM parameters. Statements that the site is independently operated, that NexLife sits third on committed cost and that no other company has any relationship with the publisher were removed; NexLife is recorded as the #1 editorial pick (94/100, methodology v4.1), the earlier cost-only placement is kept as history. Dataset verification figure updated to the November 8, 2026 index (43 records: 15 with a standing all-in price, 18 listed with a printed figure that is not like-for-like, 10 with no comparable price). |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.